GlassScriptPhysician profile
Hemantkumar G Patel
NPI 1932178357
$8,152.39
in general payments reported to CMS, 2019-2025
19 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $3,214 · 2021: $1,738 · 2022: $869 · 2023: $261 · 2024: $297 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,957.26 | 2019-2025 | Fasenra, Breztri, Lokelma |
| Glaxosmithkline, LLC. | $376.70 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $194.92 | 2024-2025 | Arikayce, Brinsupri |
| Novartis Pharmaceuticals Corporation | $96.18 | 2020-2024 | |
| Abbott Laboratories | $86.91 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $84.93 | 2024-2025 | Rexulti |
| Gilead Sciences, INC. | $77.88 | 2023-2025 | |
| Harmony Biosciences LLC | $49.99 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.70 | 2021-2024 | |
| Siemens Medical Solutions USA, INC. | $31.67 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.02 | 2021-2022 | |
| Pfizer INC. | $21.98 | 2025 | |
| Novo Nordisk INC | $18.96 | 2025 | Wegovy |
| Lundbeck LLC | $17.86 | 2024 | Rexulti |
| Allergan, INC. | $17.75 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.34 | 2024 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $15.01 | 2024 | Eliquis |
| Sunovion Pharmaceuticals INC. | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemantkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.